Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome

The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome. This study included patients who admitted in Jiangxi Provincial People’s Hospital from January 1, 2017 to December 31, 2019 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lan, Fu, Qianyu, Zhou, Longhua, Fan, Yuqin, Liu, Fenfen, Fan, Yuanyuan, Zhang, Xin, Lin, Weiqing, Wu, Xiaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688417/
https://www.ncbi.nlm.nih.gov/pubmed/34930986
http://dx.doi.org/10.1038/s41598-021-03773-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688417/
https://www.ncbi.nlm.nih.gov/pubmed/34930986
http://dx.doi.org/10.1038/s41598-021-03773-z

Ejemplares similares